StreetAlpha.app
Home › Stocks › CGEM

Cullinan Therapeutics, Inc. (CGEM)

Healthcare
$9.28
▼ −2.37%
LAST CLOSE · NOV 17

Cullinan Therapeutics develops bispecific T cell engager therapies for autoimmune diseases and cancer. It last closed at $9.28 on Nov 17, down 2.37% on the day. The average 12-month price target from 3 analysts is $40.00 (+331.3% from the last close), with a high of $44.00 and a low of $35.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 3 whale options trades in CGEM, 67% of them bullish and 33% bearish.

AI Auto Pilots
Is CGEM in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$203.5M
Free cash flow
−$165.5M
Valuation
Market cap
$602.1M
64.9M shares
P/E
–
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$88.3M
At Sep 30
Shares outstanding
64.9M
At Nov 4
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$67.5M−$67.5MFY2021FY2022: $109.2M$109.2MFY2022FY2023: −$155.1M−$155.1MFY2023FY2024: −$167.6M−$167.6MFY2024FY2025: −$219.9M−$219.9MFY2025

From CGEM's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Last report
Nov 10
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on CGEM in the past 90 days
Average 12-month target
$40.00
▲ 331.3% upside

Based on 3 analysts who set a price target on CGEM in the past 90 days. The average target is $40.00, with a high of $44.00 and a low of $35.00, compared with the last close of $9.28.

Low $35.00Avg $40.00High $44.00
Blue marker: last close $9.28
Highest target$44.00
Average target$40.00
Lowest target$35.00
Latest rating changes
WedbushTarget raised
Nov 11Buy$42 → $44
BTIGTarget raised
Oct 28Buy$40 → $41
HC Wainwright & Co.Target raised
Sep 25Buy$30 → $35
BTIGTarget raised
Sep 14Buy$39 → $40
HC Wainwright & Co.Reiterated
Aug 17Buy$30
DateFirmActionRatingPrice target
Nov 11WedbushTarget raisedBuy$42 → $44
Oct 28BTIGTarget raisedBuy$40 → $41
Sep 25HC Wainwright & Co.Target raisedBuy$30 → $35
Sep 14BTIGTarget raisedBuy$39 → $40
Aug 17HC Wainwright & Co.ReiteratedBuy$30
Loading…

Technical Analysis

CGEM · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 39% below its 20 day and 66% below its 50 day average. It is 70% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 27), oversold. The nearest support is the Pivot at $9.13, and the nearest resistance the Pivot R1 at $9.78.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 12.1%/day
Key levels
$23.1952 week high+149.9%
$17.28100 day average+86.2%
$15.79200 day average+70.2%
$15.3750 day average+65.6%
$15.32Swing high (Oct 22)+65.1%
$12.9220 day average+39.2%
$9.78Pivot R1+5.4%
$9.28Last close
$9.13Pivot−1.6%
$8.62Pivot S1−7.1%
$8.2352 week low−11.3%
Indicators
RSI (14)27.32Oversold below 30Oversold
MACD-1.61Below its signal lineBearish
Stochastic6.2Near the bottom of its rangeOversold
ADX (14)32.6Trending down
Williams %R-89.8Oversold below −80, overbought above −20Oversold
CCI (20)-125.5Oversold below −100, overbought above 100Oversold
Rate of change−41.1%Change over 10 sessionsBearish
ATR (14)$1.13Typical daily range, 12.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CGEM

What happened before

See how CGEM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Whale flow leans bullish2 bullish and 1 bearish whale options trades in the last 90 days. See Whale Flow
November seasonalityHow CGEM usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How CGEM has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
3
Bullish
2
67%
Bearish
1
33%
Date span
Nov 4 – Nov 4
Loading…

See today’s whale options flow across the market →

CGEM Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ●85 buying vs 77 selling
  • ▼Held by funds -2.5 pts
  • ▼Funds holding -2
  • ▼Superinvestors: 0 added, 4 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding182184−1.1%
In funds' top 10330.0%
Held by funds108.0%110.5%−2.5 pts
New / increased21 / 6429 / 84−24.8%
Reduced / sold out55 / 2247 / 20+14.9%
Put/call ratio–0.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CGEM institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CGEM is in one of them and how their past CGEM trades turned out.

CGEM in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CGEM in an article yet. Here's the latest on the wider market.

About Cullinan Therapeutics

Cullinan Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, that develops drug candidates for autoimmune diseases and cancer. Its main programs are bispecific T cell engagers, a type of antibody therapy designed to direct immune T cells against target cells. The company is testing these candidates in clinical trials for lupus, rheumatoid arthritis, Sjögren's disease, and acute myeloid leukemia, and it also works with a partner on an oral lung cancer treatment. Its target patients are people living with these conditions.

Headquarters
Cambridge, MA